Treatment resistant schizophrenia and neurological soft signs may converge on the same pathology: Evidence from explanatory analysis on clinical, psychopathological, and cognitive variables

被引:28
作者
de Bartolomeis, Andrea [1 ]
Prinzivalli, Emiliano [1 ]
Callovini, Gemma [1 ]
D'Ambrosio, Luigi [1 ]
Altavilla, Benedetta [1 ]
Avagliano, Camilla [1 ]
Iasevoli, Felice [1 ]
机构
[1] Univ Sch Med Federico II, Dept Neurosci, Lab Mol & Translat Psychiat, Sect Psychiat,Unit Treatment Resistant Psychosis, Naples, Italy
关键词
1ST-EPISODE SCHIZOPHRENIA; NEUROPSYCHOLOGICAL PERFORMANCE; ANTIPSYCHOTIC TREATMENT; TREATMENT RESPONSE; NEGATIVE SYMPTOMS; SCALE; ABNORMALITIES; INSTRUMENT; PREDICTORS; REMISSION;
D O I
10.1016/j.pnpbp.2017.09.002
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Here, we investigated neurological soft signs (NSSs) in treatment resistant schizophrenia (TRS) vs treatment responder schizophrenia (SZ) patients. TRS is a severe condition, affecting approximately one-third of schizophrenia patients and representing a relevant clinical challenge. NSSs are neurological abnormalities reportedly described in schizophrenia patients and linked to dysregulated network connections. We explored the possibility that NSSs may be: i) more severe in TRS patients; ii) differentially associated to clinical/cognitive variables in TRS vs SZ; iii) predictive of having TRS. In addition, we evaluated whether diagnosis may mediate NSSs associations with the above-mentioned variables. Consecutive patients with schizophrenia diagnosis underwent stringent assessment for TRS diagnosis. Demographics and clinical variables were recorded. Psychopathology (by Positive and Negative Syndrome Scale, PANSS), cognitive performances, and NSSs (by Neurological Evaluation Scale, NES) were tested. TRS had higher scores than SZ patients in total NES score and in almost all NES subscales, even after correction for duration of illness and antipsychotic dose (ANCOVA, p < 0.05). NSSs significantly correlated with multiple clinical, psychopathological, and cognitive variables (above all: duration of disease and negative symptoms) in TRS but not in SZ patients. Two-way ANOVA showed NSS-x-diagnosis interaction in determining outcomes on multiple cognitive performances, but not in other clinical variables. However, simple main effect analysis detected a significant relationship between high severity NSSs and TRS diagnosis on multiple clinical and cognitive outcomes. Hierarchical regression analysis showed that diagnosis was among a discrete number of predictors yielding significant increases in variance explained on NES total, Sensory Integration and Other Signs subscales' scores. NSSs, together with antipsychotic dose and disease severity, were found to be significantly predictive of TRS diagnosis in a binary logistic regression model. These results suggest a stringent association between NSSs and TRS diagnosis, and may imply that NSSs association with clinical, psychopathological, and cognitive variables may be in part mediated by TRS diagnosis.
引用
收藏
页码:356 / 366
页数:11
相关论文
共 77 条
  • [61] Neurological soft signs, clinical symptoms and treatment reactivity in patients suffering from first episode schizophrenia
    Prikryl, R
    Ceskova, E
    Kasparek, T
    Kucerova, H
    [J]. JOURNAL OF PSYCHIATRIC RESEARCH, 2006, 40 (02) : 141 - 146
  • [62] Neurological soft signs and their relationship to 1-year outcome in first-episode schizophrenia
    Prikryl, Radovan
    Ceskova, Eva
    Kasparek, Tomas
    Kucerova, Hana
    [J]. EUROPEAN PSYCHIATRY, 2007, 22 (08) : 499 - 504
  • [63] Dynamics of neurological soft signs and its relationship to clinical course in patients with first-episode schizophrenia
    Prikryl, Radovan
    Ceskova, Eva
    Tronerova, Silva
    Kasparek, Tomas
    Kucerova, Hana Prikrylova
    Ustohal, Libor
    Venclikova, Simona
    Vrzalova, Michaela
    [J]. PSYCHIATRY RESEARCH, 2012, 200 (2-3) : 67 - 72
  • [64] Patients with Poor Response to Antipsychotics Have a More Severe Pattern of Frontal Atrophy: A Voxel-Based Morphometry Study of Treatment Resistance in Schizophrenia
    Quarantelli, Mario
    Palladino, Olga
    Prinster, Anna
    Schiavone, Vittorio
    Carotenuto, Barbara
    Brunetti, Arturo
    Marsili, Angela
    Casiello, Margherita
    Muscettola, Giovanni
    Salvatore, Marco
    de Bartolomeis, Andrea
    [J]. BIOMED RESEARCH INTERNATIONAL, 2014, 2014
  • [65] An exploratory study of the relationship between neurological soft signs and theory of mind deficits-in schizophrenia
    Romeo, Stefano
    Chiandetti, Alessio
    Siracusano, Alberto
    Troisi, Alfonso
    [J]. PSYCHIATRY RESEARCH, 2014, 218 (1-2) : 7 - 11
  • [66] Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder
    Rossi, Alessandro
    Bagala, Anna
    Del Curatolo, Vincenzo
    Scapati, Francesco
    Bernareggi, Micaela Maria
    Giustra, Maria Grazia
    [J]. HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2009, 24 (07) : 574 - 583
  • [67] Relationships between cognitive and neurological performance in neuroleptic-naive psychosis
    Sanders, RD
    Schuepbach, D
    Goldstein, G
    Haas, GL
    Sweeney, JA
    Keshavan, MS
    [J]. JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES, 2004, 16 (04) : 480 - 487
  • [68] Baseline Striatal Functional Connectivity as a Predictor of Response to Antipsychotic Drug Treatment
    Sarpal, Deepak K.
    Argyelan, Miklos
    Robinson, Delbert G.
    Szeszko, Philip R.
    Karlsgodt, Katherine H.
    John, Majnu
    Weissman, Noah
    Gallego, Juan A.
    Kane, John M.
    Lencz, Todd
    Malhotra, Anil K.
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 2016, 173 (01) : 69 - 77
  • [69] NEUROLOGICAL SOFT SIGNS IN SCHIZOPHRENIA
    SCHRODER, J
    NIETHAMMER, R
    GEIDER, FJ
    REITZ, C
    BINKERT, M
    JAUSS, M
    SAUER, H
    [J]. SCHIZOPHRENIA RESEARCH, 1991, 6 (01) : 25 - 30
  • [70] Neurological soft signs and positive treatment response to olanzapine in chronic schizophrenia
    Sevincok, L
    Topaloglu, B
    [J]. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2006, 30 (01) : 141 - 143